BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 208 filers reported holding BRIDGEBIO PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.95 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $3,183,360 | -7.6% | 91,020 | +23.8% | 0.47% | +129.3% |
| Q3 2021 | $3,446,000 | -21.9% | 73,500 | +1.5% | 0.20% | -41.1% |
| Q2 2021 | $4,413,000 | -7.4% | 72,400 | -6.5% | 0.35% | -15.9% |
| Q1 2021 | $4,767,000 | -5.3% | 77,400 | +9.3% | 0.41% | +5.1% |
| Q4 2020 | $5,035,000 | +114.7% | 70,800 | +13.3% | 0.39% | +105.2% |
| Q3 2020 | $2,345,000 | -31.4% | 62,500 | -40.4% | 0.19% | -56.6% |
| Q2 2020 | $3,417,000 | +7.6% | 104,800 | -4.3% | 0.44% | -27.4% |
| Q1 2020 | $3,176,000 | +220.5% | 109,500 | +286.9% | 0.61% | +218.8% |
| Q4 2019 | $991,000 | – | 28,300 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |